Liposomal drug delivery systems and anticancer drugs

Temidayo O. B. Olusanya, Rita Rushdi Haj Ahmad, Daniel M. Ibegbu, James Smith, Amal Ali Elkordy

Research output: Contribution to journalArticlepeer-review

139 Downloads (Pure)


Cancer is a life-threatening disease contributing to ~3.4 million deaths worldwide. There are various causes of cancer, such as smoking, being overweight or obese, intake of processed meat, radiation, family history, stress, environmental factors, and chance. The first-line treatment of cancer is the surgical removal of solid tumours, radiation therapy, and chemotherapy. The systemic administration of the free drug is considered to be the main clinical failure of chemotherapy in cancer treatment, as limited drug concentration reaches the tumour site. Most of the active pharmaceutical ingredients (APIs) used in chemotherapy are highly cytotoxic to both cancer and normal cells. Accordingly, targeting the tumour vasculatures is essential for tumour treatment. In this context, encapsulation of anti-cancer drugs within the liposomal system offers secure platforms for the targeted delivery of anti-cancer drugs for the treatment of cancer. This, in turn, can be helpful for reducing the cytotoxic side effects of anti-cancer drugs on normal cells. This short-review focuses on the use of liposomes in anti-cancer drug delivery.
Original languageEnglish
Article number907
Number of pages17
Issue number4
Publication statusPublished - 14 Apr 2018


  • liposomes
  • anti-cancer drugs
  • drug delivery


Dive into the research topics of 'Liposomal drug delivery systems and anticancer drugs'. Together they form a unique fingerprint.

Cite this